Trospium Chloride/Xanomeline

Tier C — Watch / trade

PureTech Health PLC

Originator

2024

First approval

Expiry (public)

$0.15B ▲

Peak sales

Small molecule

Type

Targets：mAChRs, CHRM1, CHRM4

Brand：COBENFY

Indications (approved)：Schizophrenia

Regional status

Approved

2024-09-26

Phase III

2021-02-01

China

Approved

2025-12-22

Japan

Phase III

2021-11-12

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Trospium Chloride/Xanomeline?

Approved indications include: Schizophrenia.

When does the Trospium Chloride/Xanomeline patent expire?

No public expiry year is available for Trospium Chloride/Xanomeline yet; this page updates once verified.

How do I get a quote for Trospium Chloride/Xanomeline intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27